Recombinant Human CD8b Protein，His

CD8b is a crucial component of the CD8 glycoprotein family, primarily expressed on cytotoxic T lymphocytes (CTLs). It plays a fundamental role in the immune response by aiding in the recognition of major histocompatibility complex (MHC) class I molecules, which present endogenous antigens. This interaction is critical for the activation and proliferation of CTLs, enabling them to effectively target and eliminate infected or malignant cells. Research into CD8b recombinants has gained momentum in recent years due to its implications in immunotherapy and vaccine development. Studies have shown that enhancing CD8b expression or functionality can improve the anti-tumor responses in various cancer models. Additionally, recombinant CD8b proteins can be utilized as tools to investigate T cell receptor (TCR) interactions and identify novel epitopes for vaccine design. Understanding the structural and functional characteristics of CD8b can provide insights into T cell development and differentiation. Moreover, as CD8b is involved in immune evasion mechanisms employed by tumors and pathogens, targeting CD8b could open new avenues for therapeutic interventions. The ongoing exploration of CD8b recombinants not only seeks to elucidate its biological functions but also aims to leverage its properties for enhancing immune responses in clinical applications, marking it as a significant focus in contemporary immunological research.